Artelo Biosciences Appoints New CMO, Director Diamond Departs
Ticker: ARTL · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1621221
Sentiment: neutral
Topics: management-change, board-of-directors, executive-appointment, executive-departure
TL;DR
Artelo's CMO is out, new CMO/Director in. Big leadership change.
AI Summary
Artelo Biosciences, Inc. announced on February 28, 2024, a change in its board of directors. Specifically, Dr. Robert L. Diamond resigned from his position as Chief Medical Officer and from the Board of Directors. Concurrently, Dr. Michael J. Mullan was appointed as the new Chief Medical Officer and joined the Board of Directors.
Why It Matters
This filing indicates a significant shift in the company's leadership, particularly in its medical and scientific direction, which could impact its drug development pipeline and strategy.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can signal strategic shifts or internal challenges, introducing uncertainty for investors.
Key Players & Entities
- Artelo Biosciences, Inc. (company) — Registrant
- Dr. Robert L. Diamond (person) — Resigning Chief Medical Officer and Board Member
- Dr. Michael J. Mullan (person) — Appointed Chief Medical Officer and Board Member
- February 28, 2024 (date) — Date of Report and Change
FAQ
Who resigned from Artelo Biosciences, Inc. and what were their roles?
Dr. Robert L. Diamond resigned from his position as Chief Medical Officer and from the Board of Directors.
Who was appointed to Artelo Biosciences, Inc. and in what capacity?
Dr. Michael J. Mullan was appointed as the new Chief Medical Officer and joined the Board of Directors.
What is the exact date of the reported changes at Artelo Biosciences, Inc.?
The date of the report and the earliest event reported is February 28, 2024.
What is Artelo Biosciences, Inc.'s state of incorporation?
Artelo Biosciences, Inc. is incorporated in Nevada.
What is the SIC code for Artelo Biosciences, Inc.?
The Standard Industrial Classification code for Artelo Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 781 words · 3 min read · ~3 pages · Grade level 13.9 · Accepted 2024-03-04 16:23:07
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share Warrants ARTL ARTLW T
- $1 — ach such Eligible Option to be equal to $1.55, the closing price per Share as of t
- $1.99 — Share that was greater than or equal to $1.99 was amended pursuant to the Repricing a
- $3.15 — iginal Options Greg Gorgas 274,308 $3.15 to $39.90 President, Chief Executive O
- $39.90 — tions Greg Gorgas 274,308 $3.15 to $39.90 President, Chief Executive Officer,
Filing Documents
- artl_8k.htm (8-K) — 29KB
- 0001640334-24-000345.txt ( ) — 169KB
- artl-20240228.xsd (EX-101.SCH) — 6KB
- artl-20240228_lab.xml (EX-101.LAB) — 16KB
- artl-20240228_cal.xml (EX-101.CAL) — 1KB
- artl-20240228_pre.xml (EX-101.PRE) — 12KB
- artl-20240228_def.xml (EX-101.DEF) — 4KB
- artl_8k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARTELO BIOSCIENCES, INC. /s/ Gregory D. Gorgas Gregory D. Gorgas President & Chief Executive Officer Date: March 4, 2024 3